Ginkgo bioworks stocks.

Synthetic biology pioneer Ginkgo Bioworks agreed to go public today in a $17.5 billion SPAC deal. The Boston-based company will merge with Soaring Eagle Acquisition Corp., a blank-check firm ...Ginkgo Bioworks Holdings Insider Sold Shares Worth $299,400, According to a Recent SEC Filing. MT. Nov. 17. Ginkgo Bioworks Holdings Insider Sold Shares …Nov 29, 2023 · Nov. 17. Ginkgo Bioworks Holdings Insider Sold Shares Worth $299,400, According to a Recent SEC Filing. MT. Nov. 17. Ginkgo Bioworks Holdings Insider Sold Shares Worth $112,837, According to a Recent SEC Filing. MT. Summary. Quotes. Charts. Ginkgo is expecting Total revenue of $250 - $260 million in 2023. Ginkgo revised its expectations for Cell Engineering revenue to $145 - $150 million in 2023, inclusive of $4 million of downstream ...What this means: InvestorsObserver gives Ginkgo Bioworks Hldgs Inc (DNA) an overall rank of 43, which is below average. Ginkgo Bioworks Hldgs Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 43 means that 57% of stocks appear more favorable to our system.

Boston-based Ginkgo Bioworks (NYSE: DNA) is working to develop a platform to “program cells to make everything from food to materials to therapeutics.” Industries it serves include agriculture ...1. Ginkgo Bioworks. Ginkgo Bioworks is a biotech company that went public through a special purpose acquisition company last year. The company has the backing of Bill Gates and can design and ...Dec 1, 2023 · 2. Ginkgo Bioworks. Ginkgo Bioworks has scaled up the process of engineering organisms that can be used in a variety of industries, from agriculture to pharmaceuticals. Through the company's ...

Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. View the latest Ginkgo Bioworks Holdings Inc. (DNA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Ginkgo Bioworks ( DNA 5.80%) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning. What's ...2. Ginkgo Bioworks. Ginkgo Bioworks ( DNA -7.19%) also plans to be a collaboration-driven business, but its approach is a bit different. While it uses its machine learning platform to help with ...Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public. Shares opened at $11.15 apiece under ticker ...These three growth stocks to buy could provide triple-digit percentage returns for investors in the near to mid term. ... Ginkgo Bioworks : Synthetic biology is a rapidly growing space. ...

Aug 9, 2023 · Second Quarter 2023 Financial Highlights. Second quarter 2023 Total revenue of $81 million, down from $145 million in the comparable prior year period, a decrease of 44% primarily driven by the ...

Ginkgo Bioworks announces $100 million equity offering. Read more to see why it has been a very strange couple of days for DNA stock. Ginkgo Bioworks announces $100 million equity offering. Read ...

Ginkgo Bioworks ( NYSE: DNA) is a leading synthetic biology company that went public through a SPAC in 2021. A large amount of hype has surrounded Ginkgo due to its ambitions, and it managed to ...Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Ginkgo Bioworks reported Q2 revenue of $81 million, down 44% YoY, mainly due to a decline in Biosecurity revenue. Read more about DNA stock here.Food ingredient company Vivici has partnered with Ginkgo Bioworks to develop a range of new alternative dairy proteins created through precision fermentation, …The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is a Hold stock at the moment, with a recommendation rating of 2.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 9 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight.8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations.

Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Find real-time DNA - Ginkgo Bioworks Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. ... Ginkgo Bioworks Holdings Inc (NYSE:DNA) Real-Time Quotes. 1.37.Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance ...10 stocks we like better than Ginkgo Bioworks When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...According to Live Science, the Brachiosaurus was a herbivore that ate coniferous trees, ginkgoes and cycads. To maintain its weight, an adult Brachiosaurus had to eat up to 400 pounds of plants every day.Ginkgo Bioworks Holdings Inc Stock (DNA) Forecast. The Ginkgo Bioworks Holdings Inc ( DNA) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $3.8461, representing a +163.43% increase from the current price of $1.46. The highest analyst price target is $7.2822, and the lowest is $0.4100.Oct 19, 2022 · Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock. Zymergen shares will no longer be traded on Nasdaq. GinkgoClass A common stock will continue to trade on NYSE under the ticker symbol DNA.

A high-level overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Ginkgo Bioworks Holdings Inc Stock (DNA) Forecast. The Ginkgo Bioworks Holdings Inc ( DNA) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $3.8461, representing a +163.43% increase from the current price of $1.46. The highest analyst price target is $7.2822, and the lowest is $0.4100.Aug 3, 2023 · Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Bioworks (DNA 5.80%) is also a holding in the Ark Innovation ETF and the Ark Genomic Revolution ETF. The company is a leader in cell programming technology that's used in developing ...This week was one to forget for Ginkgo Bioworks ( DNA 10.85%) shareholders. In the Monday-to-Friday period, their investment lost slightly more than 8% of its value on the stock market, according ...Dec 9, 2022 ... Ginkgo Bioworks Stock Forecast - Analyst Ratings. Eight FactSet analysts have an Overweight consensus rating on DNA stock with a share price ...With Ginkgo Bioworks Holdings stock trading at $1.46 per share, the total value of Ginkgo Bioworks Holdings stock (market capitalization) is $3.09B. Ginkgo Bioworks Holdings stock was originally listed at a price of $10.88 in Feb 24, 2021. If you had invested in Ginkgo Bioworks Holdings stock at $10.88, your return over the last 2 …The firm is now DNA stock's largest shareholder. Ginkgo Bioworks (NYSE: DNA) is in the red today, despite a recent transaction with $182 billion investment firm Baillie Gifford. Based on an ...

Of the 279 institutional investors that purchased Ginkgo Bioworks stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ARK Investment Management LLC ($158.96M), Baillie Gifford & Co. ($154.42M), Sumitomo Mitsui Trust Holdings Inc. ($65.50M), Nikko Asset Management Americas Inc. …

Ginkgo Bioworks reported Q2 revenue of $81 million, down 44% YoY, mainly due to a decline in Biosecurity revenue. Read more about DNA stock here.

Here’s how four startups are programming biology to develop new products in medicine, energy, food and more. Get the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock news and headlines to help ...8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations.These three growth stocks to buy could provide triple-digit percentage returns for investors in the near to mid term. ... Ginkgo Bioworks : Synthetic biology is a rapidly growing space. ...Wood keeps buying DNA stock despite it being down more than 60% so far this year. Cathie Wood has been adding shares of biotech company Ginkgo Bioworks ( DNA) to her exchange-traded funds (ETFs ...Key Points. Cathie Wood bought shares of Palantir, Teladoc, and Ginkgo Bioworks on Thursday. Palantir's shares have more than doubled in 2023, but the three stocks are still 31% to 94% lower than ...Jul 25, 2022 · Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, ... The all-stock deal values Zymergen at $300 million market capitalization, ... First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo's ...Ginkgo Bioworks. Cathie Wood's Ark Invest is quickly building a position in a SPAC that plans to merge with Ginkgo Bioworks. The Ark Disruptive Innovation and Genomic Revolution ETFs doubled its ... Nov 6, 2023 · You can see the complete list of today’s Zacks #1 Rank stocks here. Ginkgo Bioworks Holdings, Inc. Price and EPS Surprise. Ginkgo Bioworks Holdings, Inc. Price and EPS Surprise.

Dec 1, 2023 · Many SPACs haven't lived up to their initial hype; unfortunately, Ginkgo hasn't been an exception. When its shares first began trading on the NYSE on Sept. 17, 2021, it opened at a price of $11.15 ... Second Quarter 2023 Financial Highlights. Second quarter 2023 Total revenue of $81 million, down from $145 million in the comparable prior year period, a decrease of 44% primarily driven by the ...Based on short-term price targets offered by eight analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $3.46. The forecasts range from a low of $1.25 to a high of $7.00 ...Instagram:https://instagram. voo top holdingsfast growing stocks right nowvanguard high yield bondstock price of acb Jun 7, 2022 · Those are some eye-opening estimates, particularly since the leader in synthetic biomanufacturing, Ginkgo Bioworks (DNA 2.16%), currently has a market cap of $6 billion and trades for a little ... is 3m a good stock to buyretire to canada Ginkgo Bioworks' Q2 results were poor, with soft results in both the Cell Engineering and Biosecurity businesses. ... everyone will be scrambling to buy the stock at MUCH HIGHER prices. In 2022 ...Two major developments, including a big acquisition, are moving DNA stock today. Ginkgo Bioworks ( DNA) has agreed to acquire Bayer’s ( BAYRY) research and development center. Furthermore ... advisor practice management Ginkgo Bioworks (NYSE: DNA) stock is in full focus today following ownership updates from three co-founders. The cell programming company has become a favorite of Ark Invest’s Cathie Wood.Dec 1, 2023 · Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More. Ark Invest has purchased more than 3.5 million shares of Ginkgo Bioworks since June 29.; The biotech company is now the fund’s 23rd largest holding. Shares of DNA stock are down over 65% year-to ...